In order to increase the antiarrhythmic activity of Pro-Hyp-Gly-Ala-Gly (P-5), P-5 analogues with three different hydrophobic substituents, N-3-(4-hydroxyphenyl)propionyl (H), N-3-phenylpropionyl (I) and N-3-phenylpropyl (P), were prepared and their activities were evaluated in CaC12-induced arrhythmias in mice. HP-5 showed potent antiarrhythmic activity at 1 mg/kg, i.v. and its potency was much higher than that of P-5 at 10 mg/kg, i.v. IP-5 showed similar potency to P-5, but PP-5 was inactive. Pro-Hyp-Gly-Ala, Pro-Hyp-Gly and Pro-Hyp with the substituent, H, were also ineffective. Thus, 3-(4-hydroxyphenyl)propionylation of the imino nitrogen of Pro in P-5 led to increased potency. Keywords peptide analogue; antiarrhythmic effect; CaCl2 arrhythmias; mouse A hexapeptide (antiarrhythmic peptide, AAP), isolated from bovine atria1) and identified as Gly-Pro-Hyp-Gly-Ala-Gly, 2) showed a protective effect against experimental druginduced arrhythmias in cultured myocardial cells of rats1) and whole hearts of dogs, rats and mice.3) Although several investigations have been done on the structure-activity relationship of AAP analogues including its fragments and collagen peptides, all the tested analogues were ineffective.1,2,4) In this paper, potent antiarrhythmic activity of a new analogue, Pro-HypGly-Ala-Gly with a hydrophobic substituent at its amino-terminus, is demonstrated.
Experimental Analogues
The peptide analogues, listed in Table  I Results and Discussion
We have reported that the AAP analogues including Gly-Pro, Gly-Pro-Hyp, Gly-ProLeu, (Pro-Pro-Gly)5, Gly-Pro-Hyp-Gly, Gly-Pro-Leu-Gly-Pro, Hyp-Gly-Ala-Gly, GlyAla-Gly, Gly-Gly-Gly and 9 kinds of collagen peptides, whose sequences differ by only one amino acid from that of AAP, showed no antiarrhythmic activity.1,2,4) Among newly synthesized fragments including P-5, P-4, P-3 and P-2, only P-5 showed almost the same antiarrhythmic activity at 10 mg/kg, i.v. as AAP and quinidine sulfate in CaC12-induced arrhythmias in mice, as shown in Table II . Therefore, it is probable that the penta amino acid sequence of P-5 is the minimum essential requirement for the antiarrhythmic activity of the peptide. However, intravenously administered P-5 might show low activity because of the high hydrophilicity of the chemical structure. Thus, in order to increase the activity of P-5, P-5 analogues with three different hydrophobic substituents, N-3-(4-hydroxyphenyl)propionyl, N-3-phenylpropionyl and N-3-phenylpropyl, were prepared and their antiarrhythmic activities were evaluated (Table II) . HP-5 showed potent antiarrhythmic activity at 1 and 10 mg/kg, i.v. and its protective effect (prolongation) was much higher than that of P-5. IP-5 showed similar potency to P-5, but PP-5 was inactive. As regards the structure-activity relationship, acylation (HP-5 and IP-5) of the imino nitrogen of Pro in P-5 was necessary for the activity, because alkylation (PP-5) of the imino nitrogen reduced the activity. Further, hydroxylation of the phenyl group was most effective, because HP-5 was much more potent than IP-5. On the other hand, peptide fragments with the N-3-(4-hydroxyphenyl)propionyl group, HP-4, HP-3 and HP-2, were ineffective, as shown in Table II . Therefore, the potent antiarrhythmic activity of HP-5 was not due only to the substituent. Thus, 3-(4-hydroxyphenyl)propionylation of the imino nitrogen of Pro in P-5 led to increased potency. Effect of Peptide Analogues on CaC12-Induced Arrhythmias in Mice a) Sample or saline (control) was administered intravenously 3 min before the start of CaCl2 infusion (3 mg/0.1 ml/25 g body weight/min). b) Onset time of arrhythmias induced by CaCl2 infusion was measured. See Experimental for details. c) p <0.05, d) p<0.001: versus control.
